Announcement for OBIGEN that its Phase 2 study for OBI-858 received positive final results and met primary and secondary endpoints with statistical significance

Date of occurrence of the event:2025/08/22 New drug name or code: OBI-858 Novel Botulinum Neurotoxin Indication:OBI-858 is a novel botulinum neurotoxin (BoNT) developed using OBIGEN’s proprietary bacteria, intended for both aesthetic and therapeutic applications. The product was discovered and developed in Taiwan and possessed a unique molecular weight. It has been granted patents in multiple […]